Business Context and Reporting Period
This Form 8-K is a current report filed by Akebia Therapeutics, Inc. on May 9, 2023. The filing addresses a regulatory notice received from The Nasdaq Stock Market LLC regarding the Company's compliance with listing standards.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and listing status.
Material Changes
- Delisting Notice: On May 9, 2023, the Company was notified by Nasdaq that its securities are subject to delisting due to non-compliance with the minimum bid price requirement (Nasdaq Listing Rule 5550(a)(2)) as of May 8, 2023.
- Grace Period Expiration: The Company had previously been granted two consecutive 180-calendar day grace periods (notified May 13, 2022, and November 10, 2022) to regain compliance. The final grace period expired on May 8, 2023, without the Company evidencing compliance.
- Appeal Initiation: The Company plans to timely request a hearing before the Nasdaq Hearings Panel. This request will stay further delisting action pending the Panel's decision.
Outlook, Risks, and Management Commentary
- Management Action: The Company is diligently working to regain compliance with the minimum bid price rule.
- Contingency Plan: If delisted from Nasdaq, the Company expects its securities to be eligible to trade on the over-the-counter (OTC) Markets platform.
- Uncertainties: There is no assurance that the Hearings Panel will grant the appeal, grant an extension of time, or that the Company will be able to regain compliance within any granted extension period.
- Forward-Looking Statements: The filing includes standard disclaimers regarding risks associated with the timing of the hearing, the outcome of the appeal, and the ability to meet listing standards.
Investor Verification Checklist
- Verify the current trading status of Akebia Therapeutics (AKBA) on Nasdaq versus OTC markets.
- Monitor the outcome of the appeal hearing before the Nasdaq Hearings Panel.
- Review the Company's recent stock price history to assess the likelihood of regaining the minimum bid price requirement.
- Check for subsequent filings regarding the extension period granted by the Panel, if any.